Toxic Chemicals

New Markers for the MycoTOX Profile

MattBlogPic.png

Welcome back to the GPL blog.  I have another exciting announcement and that is that we are adding four additional markers to our MycoTOX Profile, which screens for exposure to mycotoxins from mold.  Yet again, our laboratory scientists have shown why we are an industry leader in toxin exposure assessment.  These four new markers will now give us 11 markers on our revolutionary MycoTOX Profile.  These additional markers are also being added at no additional cost.

MycoTOX logo.png

Just by ordering the MycoTOX Profile you will get these four new markers in addition to the previous seven markers.  This test can be easily be added to the GPL-TOX (Toxic Non-Metal Chemical Profile) and the Organic Acids Test (OAT), all with just one first morning urine sample. 

Here are the new markers that we will be starting to report today. These four new markers will further help practitioners determine the underlying causes of their patients’ chronic health issues:

Gliotoxin
Gliotoxin (GTX) is produced by the mold genus AspergillusAspergillus spreads in the environment by releasing conidia which are capable of infiltrating the small alveolar airways of individuals.  In order to evade the body’s defenses Aspergillus releases Gliotoxin to inhibit the immune system.  One of the targets of Gliotoxin is PtdIns (3,4,5) P3.  This results in the downregulation of phagocytic immune defense, which can lead to the exacerbation of polymicrobial infections.  Gliotoxin impairs the activation of T-cells and induces apoptosis in monocytes and in monocyte-derived dendritic cells.  These impairments can lead to multiple neurological syndromes.

Mycophenolic Acid
Mycophenolic Acid (MPA) is produced by the Penicillium fungus.  MPA is an immunosuppressant which inhibits the proliferation of B and T lymphocytes.  MPA exposure can increase the risk of opportunistic infections such as Clostridia and Candida. MPA is associated with miscarriage and congenital malformations when the woman is exposed in pregnancy. 

Dihydrocitrinone
Dihydrocitrinone is a metabolite of Citrinin (CTN), which is a mycotoxin that is produced by the mold species Aspergillus, Penicillium, and Monascus.  CTN exposure can lead to nephropathy, because of its ability to increase permeability of mitochondrial membranes in the kidneys.  The three most common exposure routes are through ingestion, inhalation, and skin contact.  CTN has been shown to be carcinogenic in rat studies.  Multiple studies have linked CTN exposure to a suppression of the immune response. 

Chaetoglobosin A
Chaetoglobosin A (CHA) is produced by the mold Chaetomium globosum (CG).   CG is commonly found in homes that have experienced water damage.   Up to 49% of water-damaged buildings have been found to have CG.  CHA is highly toxic, even at minimal doses.  CHA disrupts cellular division and movement.  Most exposure to CG is through the mycotoxins because the spores tend not to aerosolize.  Exposure to CHA has been linked to neuronal damage, peritonitis, and cutaneous lesions.

Species of Mold

These new markers are adding to our already revolutionary test. We will now be able to detect over 40 different strains of disease-causing mold.Here is a table that illustrates all of the different mold species that we can now detect:

Myco and Strain Chart.jpg

We are also instituting some new changes to our MycoTOX Profile test report.  We are moving all of the interpretations to the end of the report so that all of the results will fit on the first two pages.  In addition, we are changing the reportable range.  Since we launched this test we have analyzed thousands of samples.  By analyzing those results and comparing them to results from our Organic Acids Test, we now have a better understanding of what could be considered “normal values” for mycotoxins.  On our new report (seen below) you will see two numbers on the bar graph for each marker.  The number on the left is what we consider the maximum safe amount of mycotoxins a patient can have before symptoms may start to appear.  The number on the right is our 75% for our patients.  If your value is above this number then you have more mycotoxins than 75% of patients that have sent in samples.  These should be considered extremely elevated amounts and treatment is highly recommended. 

Screen Shot 2018-10-24 at 4.12.38 PM.png

Practitioner Training – GPL Academy Practitioner Workshops

I recommend to all practitioners that they attend our training workshops to help better understand how to evaluate the results from our tests, as well as to learn what treatments have been most effective.  Our GPL Academy workshops are great learning experiences.  At these events you can talk to our laboratory experts as well as discuss treatment plans with practitioners that we invite that are experts in their fields.  Please follow this link to find a workshop near you.


PMID
16712786, 27048806, 21575912, 23278106, 858824, 28646113, 27809954, 27599910, 11567776, 24048364, 10788357, 21196335, 12781669, 17551849, 28430618, 25264878, 21954354, 27401186, 28007639, 28718805, 21872054

ELISA Versus LC/MS for Mycotoxin Testing

MattBlogPic.png

Welcome back to the GPL Blog.  Since we released our new GPL-MycoTOX Profile, we’ve received many questions about what the differences are between the types of mycotoxin testing available, why we use the technology that we do (LC/MS), and why we believe that technology is superior.  I wanted to share our feedback about that with you, including support data in the form of some split sample reports. 

The Difference Between ELISA and LC/MS

MycoTOXLogoMoldy Room.png

ELISA testing is notorious for false positive readings.  ELISA principal is a lock and key activation.  If any molecule fits the lock then the result shows up positive.  One of the criticisms often heard about mold testing is the over-abundance of positive results. The literature backs up this observation with findings that show inferences that cause false positive results.  At Great Plains, we use LC/MS, not ELISA.  LC/MS separates out molecules by their chemical properties and measures their mass, so we get a definitive answer for every sample.  We also use internal standards in every sample to give a definitive quantitative reading. 

Why Creatinine Correction is Important

There are many factors that could influence the value for any urine test, including how recent the exposure was, how much the patient is detoxifying, and how much liquid the patient drank the night before giving the sample.  We are able to correct for the third of these reasons by measuring the amount of creatinine in the sample, which compensates for how diluted the sample may be.  A particular sample one of our practitioner clients asked us about was more concentrated than most (creatinine was 166 mg/dL).  If the value was 80 mg/dL, then the value would have been doubled.  This allows us to mitigate one factor that can cause mycotoxin test values to fluctuate.

We have received a couple dozen results from patients that run a test for mycotoxins from another lab, then have run our test.  We have seen the gamut of results such as their previous test coming back negative and ours is positive (see examples here  – Patient 1 with GPL and Patient 1 with RTL), both tests were positive (see example here -- Patient 2 with GPL and Patient 2 with RTL), and values where the patient was negative on both. 

The Clinical Significance of our Mycotoxin Test and Organic Acids Test

In our experience, no patients are “normal” when it comes to toxins, including mycotoxins.  We see mycotoxin in almost every patient, but we have set our reportable limits to only patients that we feel have abnormal amounts of mycotoxin in order to not alarm patients.  We have followed this up with a study of 50 patients with mycotoxins.  If you look at this file, we did a comparison of patients with mycotoxins to patients without mycotoxins.  We see numerous values elevated on our Organic Acids Test (OAT) in the mycotoxin positive individuals, demonstrating that our test can predict health problems for individuals.  We will soon have more information available about the connection with specific fungal markers on the Organic Acids Test 

Please let me know if you have any questions about our GPL-MycoTOX Profile and we look forward to our continued work with you. 

Matt Pratt-Hyatt, PhD
Associate Laboratory Director

The Connection Between Chronic Inflammation and Disease

MattBlogPic.png

Welcome back to the GPL blog.  Today I wanted to talk about the link between inflammation and chronic disease.  The mission of The Great Plains Laboratory is to help those suffering from chronic diseases, and recent studies have shown that most chronic diseases are tied to inflammation.  In this blog post I am going to give a brief synopsis of some of the most common diseases associated with chronic inflammation and what tests we offer that give insight into how to treat these patients.    

Inflammation is a response from the body to assist in the elimination of pathogens and to repair tissue damage from trauma.  Inflammation is a healthy, natural response to cellular stress caused by stimuli perceived as a threat.  It signals the body to bring extra nutrition to sites that are damaged through injury or illness.  Without inflammation proper healing could not occur. While acute inflammation is critical to our well-being, chronic, long term inflammation is damaging to cells and linked to many diseases. Chronic inflammation occurs when the immune system believes there is a threat even when there is no immediate reason for this perceived threat. It is still unclear what causes chronic inflammation but lifestyle factors, genetic factors, and internal stressors have all been implicated.

Recent studies have demonstrated that inflammation is an underlying contributor to most chronic diseases.  Some of the most common of these include cancer, rheumatoid arthritis, Crohn’s disease, depression, stroke, heart disease, and diabetes.   Since inflammation is involved with so many chronic diseases, detecting inflammation is an important aspect to managing patient symptoms. Better still, if the underlying causes of inflammation such as Candida, bacteria, mold, food sensitivities, and environmental toxins are determined, the disease process may be reversed.

Phospholipase A2

Picture1.png

We developed the Phospholipase A2 (PLA2) Activity Test to determine if a specific type of inflammation is underlying the patient’s condition.  PLA2 is an enzyme that activates during bacterial infection, cellular trauma, and periods of oxidative stress.  PLA2 activates a cascade of secondary messengers that can lead to cycles of inflammation that can self-perpetuate.  PLA2 metabolizes membrane glycerophospholipids to free arachidonic acid (AA), which is a precursor for the inflammatory signaling molecules, prostaglandins and leukotrienes (Figure 1).  PLA2 is expressed in neuronal tissue and is involved in the degranulation process that releases neurotransmitters from neurons. Research efforts have focused on the role that derangement of normal PLA2 activity plays in the etiology of many chronic illnesses. The specific roles, interactions, and interdependencies of PLA2 have been a major area of interest as it relates to chronic inflammatory conditions, cardiovascular disease, and cancer.  

Measurement of PLA2 is emerging as an important tool for evaluating the chance of cardiovascular disease (CVD), including future stroke, myocardial infarction, heart failure, and other vascular events. Lp-PLA2 appears to be more specific than hsCRP for CVD risk and may also have a pivotal role as a mediator of cardiovascular pathology. In atherosclerosis, PLA2 not only activates macrophages and formation of foam cells, but it also hydrolyzes LDL and HDL, spawning increased numbers of pro-atherogenic small LDL particles, and impairing anti-atherogenic HDL. PLA2 activity may even precipitate bleeding from atherosclerotic plaques.

Picture2.png

Because PLA2 is a relatively small enzyme (about 14 KD), it is able to be excreted in urine.  Our enzymatic assay determines how active PLA2 is in the body, which is mediated by phosphorylation of the enzyme.  We have assessed that an activity level of PLA2 activity/creatinine of over 1 results from elevated activity and could be harmful. 

CDP-choline

The literature indicates that Cytidine 5-diphospho-choline (CDP-choline or citicoline) attenuates PLA2 through a number of mechanisms. Most notably it repairs membrane potential and reduces lipid peroxidation. These processes essentially prevent new PLA2 from forming by stopping the cycle of inflammation.   Individuals with methylation pathway SNPs may be more susceptible to deficiencies in CDP-choline because it is difficult for them to make phosphoethanolamine, a CDP-choline precursor. Some individuals may have further deficiencies in citicholine due to mutations in their PEMT gene which converts phosphoethanolamine into CDP-choline. Fortunately, this compound is available as a nutritional supplement from New Beginnings Nutritionals and has been used at doses ranging from 500-4000 mg per day in the treatment of patients with a variety of disorders including Parkinson's disease, memory disorders, vascular cognitive impairment, vascular dementia, senile dementia, schizophrenia, Alzheimer's disease (especially effective in those with the epsilon-4 apolipoprotein E genotype), head trauma, and ischemic stroke. A trial in patients with Alzheimer's disease indicated that CDP-choline (1,000 mg/day) is well tolerated and improves cognitive performance, cerebral blood perfusion, and the brain bioelectrical activity pattern. No side effects were noticed except for some mild gastrointestinal symptoms at higher doses. No abnormal blood chemistry or hematology values were found after the use of CDP-choline. Many patients and practitioners are unfamiliar with CDP-choline and may be tempted to use the more commonly prescribed phosphatidyl-choline. These two products cannot be used interchangeably. Phosphatidyl-choline is a glycerophospholipid that PLA2 can use to elicit its inflammatory effects. Individuals with elevations in PLA2 should refrain from supplements containing phosphatidyl-choline and use CDP-choline instead. 

The Organic Acids Test

The Organic Acids Test (OAT) is a comprehensive metabolic assessment of multiple systems in the body.  It is one of our best tools in determining the underlying causes of many chronic diseases.  The OAT test can be useful in the identification of intestinal yeast and bacteria, oxalates, abnormal neurotransmitters, mitochondrial markers, fatty acid oxidation, nutritional deficiencies, detoxification markers, and inborn errors of amino acid metabolism.   

Many of the markers on the OAT can help in the diagnosis of inflammation.  Some of these include markers for Candida and clostridia.  An overgrowth of these pathogenic microbes can lead to disruptions in the gut lining, which can cause inflammation and disrupt the absorption of nutrients.  Candida and clostridia can also produce many different chemical toxins that are absorbed through the intestines.  These toxins can produce confusion (brain fog), thyroid dysregulation, weight gain, acne, drowsiness, irritable bowel syndrome, and insomnia.  There are multiple markers for both Candida and Clostridia.  Some of the most common yeast markers are tartaric, arabinose, and carboxycitric.       

Picture3.png

The OAT also has more metabolic markers for clostridia than any other organic acid test on the market.  The OAT is able to identify overgrowth from multiple different strains of clostridia.  This is accomplished by looking at four different markers which include 4-hydroxyphenylacetic, HPHPA, 4-Cresol, and 3-indoleacetic.   These toxins produced by bacteria can lead to inflammation as well as inhibition of neurotransmitter metabolizing enzymes.

Picture4.png

One of the best markers for inflammation is the succinic acid marker.  Succinic acid is generated in mitochondria during the tricarboxylic acid cycle (TCA).  Succinic acid is also a signaling molecule which can change gene expression patterns by modulating epigenetic markers in the DNA.  Our data indicates that exposure to environmental toxins can cause inflammation, resulting in accumulation of succinic acid.

Picture5.png

Screen Shot 2017-10-16 at 7.55.45 AM.png

 This may be caused by the inhibition of succinate dehydrogenase, an important enzyme that functions in both the Krebs cycle and complex II of the electron transport chain. In the Krebs cycle, it converts succinate to fumarate. In the electron transport chain, it works with CoQ10 to transfer electrons into the complex III phase of the chain.  Our laboratory compared patients with high values several common environmental toxins on the GPL-TOX test and determined what their average succinic acid values were.  We found that patients with high vinyl chloride, xylene, heavy metals such as lead and mercury, DMP, DEP, and 2,4 D correlated with patients having elevated succinate values (see graph).

One additional marker on the Organic Acids Test for inflammation is quinolinic acid.  Quinolinic acid is a neuroactive metabolite of the kynurenic pathway.  Quinolinic acid is produced from tryptophan through a multi-stage process.  Buildup of quinolinic acid increases stimulation to NMDA glutamate receptors and inhibits the reuptake of glutamate by astrocytes leading to neurotoxicity.  Studies have shown that chronic exposure to quinolinic acid can lead to structural changes such as dendritic beading, microtubular disruption, and a decrease in organelles in neurons.  Quinolinic acid can also increase oxidative stress by inducing NOS activity.  Quinolinic acid further adds to inflammation by causing an increase of expression in the inflammatory response elements TNF-α and interleukin-6. 

Tests for Environmental Toxins

One of the leading causes of inflammation is environmental toxicants, which has been increasing every year since the 1960s.   This increase in toxic burden observed in our patients is one reason why we have put a focus on providing testing for many different sources of environmental toxicants.  We currently offer the GPL-TOX (Toxic Non-Metal Chemical Profile), Glyphosate Test, and metals tests (hair, urine, blood), and we just launched the GPL-MycoTOX Profile, the most sensitive test for mold toxins in the world.  If you have any questions about any of these tests, you may review previous blogs about them here or visit the individual tests information pages on our web site.  

Picture7.png

The IgG Food Allergy Test

Picture8.png

Testing for food sensitivity has been extremely helpful to many of our patient populations.  The symptoms of food sensitivity can include (but aren’t limited to) austim, ADD, depression, arthritis, fatigue, skin rashes, and gastrointestinal issues.  Our IgG Food Allergy Test is an invaluable tool to determine what role food plays in inflammation in the body. Immunoglobulin G (IgG) is the major antibody found in serum, and our test measures IgG subclasses 1-4.  IgG has a much longer half-life than the transitional IgE antibody.  Whereas IgE can cause acute reactions to food, IgG can cause inflammation that can lead to more chronic health issues.  These IgG reactions can be more subtle and people can live with them for years without realizing what is causing their discomfort.  The degree of severity can differ because of genetics or from exposure to different environmental toxins, which can predispose people to immune responses. 

At The Great Plains Laboratory we offer two different ways to submit samples for IgG food testing – serum and dried blood spot (DBS).  We have validated both of these tests against each other and they provide the same result.  Our test currently looks at 93 different foods along with testing for Candida antibodies. 

Conclusion

At The Great Plains Laboratory, we are very focused on helping patients solve their chronic health problems.  Research shows that inflammation plays a role in most chronic issues.  This is the reason why we have developed so many tests to help pinpoint the root causes of inflammation and to help figure out the best method of treatment.  We hope that we can help as many people in the future live better and longer lives.

 

 

New Analytes for GPL-TOX

Today is a very exciting day for me.  I really love when we unveil new tests or improved tests.  Today is the latter.  Our scientists have worked very hard to make our tests the best in the industry.  We want to make sure that they can be as useful to the community as possible.  We also strive to make them as affordable as possible.  That is why I’m excited to announce the addition of eight new analytes to the GPL-TOX test at no addition cost.  Just by ordering our GPL-TOX you will get these eight new analytes in addition to the previous analytes and it is still just the one first morning urine sample that is needed.


Here are our new analytes, listed with the parent first and the metabolite we are measuring in parentheses.

Acrylamide N-acetyl-S-(2-carbamoylethyl)-cysteine

Acrylamide can polymerize to form polyacrylamide.  These chemicals are used in many industrial processes such as plastics, food packaging, nail polish, cosmetics, dyes, and treatment of drinking water.    Food and cigarette smoke are also two major sources of exposure.  Acrylamide has been found in foods like potato chips and French fries.  This is because asparagine, an important amino acid for central nervous system function, can produce acrylamide when cooked at high temperature in the presence of sugars.  Foods rich in asparagine include asparagus, potatoes, legumes, nuts, seeds, beef, eggs, and fish, so use caution when cooking these foods at high temperatures.   High levels of acrylamide can elevate a patient’s risk of cancer.  In addition, acrylamide is known to cause neurological damage. 

Acrylonitrile (N-acetyl(2-cyanoethyl)cysteine)

Acrylonitrile is a colorless liquid with a pungent odor.  It is used in the production of acrylic fibers, resins, and rubber.  Use of any of these products could lead to exposure to acrylonitrile.  Smoking tobacco and cigarettes is another potential exposure.  Exposure to acrylonitrile can lead to headaches, nausea, dizziness, fatigue, and chest pains.  The European Union has classified acrylonitrile as a carcinogen.

Diphenyl phosphate

This is a metabolite of the organophosphate flame retardant triphenyl phosphate (TPHP), which is used in plastics, electronic equipment, nail polish, and resins.  TPHP can cause endocrine disruption.  Studies have also linked TPHP to reproductive and developmental problems. 

Perchlorate

This chemical is used in the production of rocket fuel, missiles, fireworks, flares, explosives, fertilizers, and bleach.  Studies show that perchlorate is often found in water supplies.  Many food sources are also contaminated with perchlorate.  Perchlorate can disrupt the thyroid’s ability to produce hormones.  The EPA has also labeled perchlorate a likely human carcinogen.  Patients that are high in perchlorate can use a reverse osmosis water treatment system to eliminate the chemical from their water supply.

1,3 butadiene (N-acetyl (3,4-dihydroxybutyl) cysteine)

This is a chemical made from the processing of petroleum.  It is often a colorless gas with a mild gasoline-like odor.  Most of this chemical is used in the production of synthetic rubber.  1,3 butadiene is a known carcinogen and has been linked to increased risk of cardiovascular disease.  Individuals that come into contact with rubber, such as car tires, could absorb 1,3 butadiene through the skin.  The increased use of old tires in the production of crumb rubber playgrounds and athletic fields is quite troubling.  

Propylene oxide (N-acetyl(2,hydroxypropl) cysteine)

This chemical is used in the production of plastics and is used as a fumigant.   Propylene oxide is used to make polyester resins for textile and construction industries.  It is also used in the preparation of lubricants, surfactants, and oil demulsifiers,  as well as a food additive, an herbicide, a microbicide, an insecticide, a fungicide, and a miticide.  Propylene oxide is a probable human carcinogen. 

1-Bromopropane (N-acetyl (propyl) cysteine)

1-BP is an organic solvent used for metal cleaning, foam gluing, and dry cleaning.  Studies have shown that 1-BP is a neurotoxin as well as a reproductive toxin.  Research indicates that exposure to 1-BP can cause sensory and motor deficits.  Chronic exposure can lead to decreased cognitive function and impairment of the central nervous system.  Acute exposure can lead to headaches.

Ethylene oxide ( N-acetyl(2-hydroxyethl)cysteine)

Ethylene oxide is used in many different industries including agrochemicals, detergents, pharmaceuticals, and personal care products.  Ethylene oxide is also used as a sterilizing agent on rubber, plastics, and electronics. 

Chronic exposure to ethylene oxide has been determined to be mutagenic to humans.  Multiple agencies have reported it as a carcinogen.  Studies of people exposed to ethylene oxide show an increased incidence of breast cancer and leukemia.  Caution is needed with ethylene oxide because it is odorless at toxic levels. 

I think these new compounds are going to make the GPL-TOX profile that much more useful.  If you are concerned about your toxic burden, we believe that this test will give you the most comprehensive assessment of your exposure.  I really hope we’ve created a test that can be a useful tool in achieving better health for you and your patients.

More Sources of Information About the Dangers of Glyphosate

More Sources of Information About the Dangers of Glyphosate

GPL was at the Environmental Health Symposium, March 4-6 in San Diego, where we were able to showcase our GPL-TOX Profile and Glyphosate Test with everyone who attended.  The response was rather amazing.  Glyphosate is the primary chemical in RoundupTM and is the world's most widely used herbicide.  Prominent glyphosate researcher, Gilles-Eric Séralini spoke ath the conference on Sunday and did a segment with the local FOX affiliate in San Diego as well.  Click the video to watch

GPL-TOX: Managing our Toxic Environment

Welcome back to the GPL blog.  I am really excited to be entering our second month of providing what we hope is useful information to the community.  Last month I discussed some of the uses of the GPL-SNP1000 test.  This month we will be discussing environmental toxicants.  Some of the topics covered will be the most prevalent toxicants in our environment, the best way to test for them, and relevant case studies. In the last blog this month I’ll cover some ways to detoxify the body and what tests can determine how well a patient is able to detoxify.

The Great Plains Laboratory introduced GPL-TOX (our toxic organic chemical profile) last July that measures 168 different toxic chemicals.  Our goal was to provide a test that measured as many chemicals as possible for a reasonable price.   These compounds fall into the categories of phthalates, benzene, pyrethrin insecticides, xylenes, styrene, fuel additives, 2,4-Dicholrophenoxyacetic (2,4-D), and organophosphate pesticides. Once a person has been exposed, the chemicals undergo several metabolic changes in the process of elimination and detoxification.  We measure the end products in the urine to determine how much chemical exposure has taken place.  Last October we introduced a test for the toxic compound glyphosate which is the world’s most widely produced herbicide. You have probably heard of it already, as it is the active ingredient in the broad-spectrum herbicide Roundup TM.  

Here at GPL, our scientists are continually working to improve our tests.  Later this month we are introducing eight new analytes to our GPL-TOX test for no additional cost. The new analytes are acrylamide, acrylonitrile, diphenyl phosphate (fire retardant metabolite), perchlorate, butadiene metabolite (carcinogenic component of rubber), dimethyl thiophosphate (pesticide metabolite),  propylene oxideacid and bromopropane.  Even before our recent update, GPL-TOX was one of the most comprehensive toxic chemical tests available.  Next week, I will discuss how all of these new analytes can affect a patient’s health.   This week I am going to provide more details about the analysis and review  a few of our current toxic analytes. I am also going to provide a few examples of case studies.   

To better understand the relevance of GPL-TOX, I’d like to explain the percentiles on our report.  The CDC issues a report of the exposure of many different chemicals to the US population.  Our percentiles are pulled from these reports.  If you are in the 95th percentile, then that means that only 5 percent of the population would have a higher value than yourself.  Since we do not know what the safe amounts are for many of these compounds we recommend reducing levels as much as possible. 

Every year over 1,000 million tons of organophosphates are used in the agricultural industry and in our home gardens.  This is a problem that is affecting us all, because even if we eat exclusively organic food, there is evidence that many of these organophosphates have contaminated the water supply.  The evidence of this has been centered on the increasing prevalence of depression, ADHD, pervasive developmental disorder, and birth defects, linking these toxins to these disorders. GPL-TOX looks at two metabolites related to organophosphates, Dimethylphosphate (DMP) and diethylphoshate (DEP).  Together these two metabolites allow us to track over 151 different organophosphates through urine, including nine of the ten most commonly used organophosphates. 

Another marker that makes GPL-TOX useful is monoethylphlate (MEP), which is a metabolite of phthalate exposure.  Many of us know about the pervasiveness of these compounds, which seem to be found in so many common products.  These products include lubricants, paints, perfumes, children’s toys, gels, and pesticides.  We are seeing many of our sickest patients possessing high values of phthalates.  Some of the symptoms we are seeing are fatigue, depression, ADHD, and arthritis.   

I want to share a couple of case studies to help illustrate what we are seeing.  The first is a painter with arthritis, fatigue, and depression.  The MEP on this patient’s GPL-TOX report came back at 19,110 (see Figure 1), which was ten-fold higher than our 95th percentile.  We recommended a detoxification program to this patient, which many of our patients are using with great success.  I will discuss different means of detoxification in my blog on May 30th, so check back for that.

 Figure 1

Figure 1

Here is one more interesting case study.  We have all heard about fracking (the process of injecting liquid chemicals at high pressure far underground, in order extract natural gas or oil) and some of the resulting damage it does to the environment and our water supplies. The results below are from an extremely autistic patient with PANDAS who lives near fracking wells in the summer (see figures 2-4).  This sample was taken months after he was exposed.

 Figure 2

Figure 2

 Figure 3

Figure 3

 Figure 4

Figure 4

These results are pretty alarming.  Obviously not everyone has high values like this, but even if we don’t live near fracking sites, we are exposed to toxic chemicals in our environment more and more every day.  If you do come up high for one or more of these chemicals, there is hope.  On May 30th I will discuss potential treatment options to detoxify the body and recommendations to avoid future exposures.  After treatment and avoidance, I recommend running the test again to make sure that you have sufficiently decreased the toxicants. 

Next week I will talk about the new analytes for the GPL-TOX test and why measuring these particular analytes is important.  In the meantime, stay vigilant about the many chemicals you and your family may be exposed to on a regular basis in every area of your home, from the food you eat and the water you drink, to all your household products.

Email gplblog@gpl4u.com if you have any questions about this blog post.